SEC Form 4 · accession 0001213900-16-011555
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Jacob
Director
Period of report
Mar 10, 2016
Accepted (ET)
Mar 14, 2016 · 2:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 10, 2016 | S | 8,500 | $6.452 | D | 16,396 | D | |
| Common Stock | holding | — | — | — | 700 | I | By wholly-owned corporation |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.41 to $6.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.